Maximum quantity allowed is 999
请选择数量
CAS RN: 155648-60-5 | 產品號碼: M2360
Minodronate Monohydrate
×
![]()
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 | 左側以上貨期 |
貨期資訊
|
|---|---|---|---|---|---|
| 25MG |
NT$9,040
|
20 | ≥40 | 下單後約2週內可以出貨 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | M2360 |
| 純度/分析方法 | >98.0%(HPLC) |
| 分子式 / 分子量 | C__9H__1__2N__2O__7P__2·H__2O = 340.17 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 包裝和容器 | 25MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 155648-60-5 |
| 相關CAS RN | 180064-38-4 |
| Reaxys-RN | 19668048 |
| PubChem Substance ID | 253660080 |
| MDL編號 | MFCD00890772 |
產品規格
| Appearance | White to Light yellow to Light red powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| NMR | confirm to structure |
性質
| 水溶性 | Insoluble |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H301 : Toxic if swallowed. H361 : Suspected of damaging fertility or the unborn child. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | SZ8562470 |
運輸資料
| UN編號 | UN2811 |
| 類別 | 6.1 |
| 包裝類別 | III |
| HS編碼* | 2933.99-000 |
Application
Bone Resorption Inhibitor
Bisphosphonates (BPs), including minodronate, ibandronate, etc., are very effective inhibitors of bone resorption in vivo and in vitro. Minodronate monohydrate (1) is one of BPs.1,2) These compounds are characterized by two C-P bonds which are located on the same carbon atom, i.e. geminal BPs, and have been used for many research studies regarding bone metabolism.1,2)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
According to differences in the side chain, BPs can be divided into two groups, non-nitrogen containing BPs (non-N-BPs) and nitrogen-containing BPs (N-BPs). 1 is a N-BP and is classified as a third-generation heterocyclic N-BP.2,3) N-BPs inhibit farnesyl pyrophosphate synthetase, a key enzyme in the mevalonate pathway, which affects cellular activity and survival.1,2) Regarding inhibition of bone resorption, 1, as well as zoledronic acid, is more effective than other BPs.4)
References
- 1)Bisphosphonates from bench to bedside
- 2)Computational insights into binding of bisphosphonates to farnesyl pyrophosphate synthase
- 3)A review of minodronic acid hydrate for the treatment of osteoporosis
- 4) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
考研文獻
文章/手冊
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。